Загрузка...
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in 20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer outcomes, compared to non-NRAS-mutant melanoma. Despite promising preclinical data, to date immune checkpoint inhibitors remain t...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8202735/ https://ncbi.nlm.nih.gov/pubmed/34135599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S278095 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|